Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
AstraZeneca
Merck Sharp & Dohme LLC
Genmab
Mayo Clinic
BioNTech SE
Aminex Therapeutics, Inc.
Toray Industries, Inc
STORM Therapeutics LTD
Neonc Technologies, Inc.
Hummingbird Bioscience
University of Wisconsin, Madison
Ipsen
Bristol-Myers Squibb
Bristol-Myers Squibb
Children's Oncology Group
Diakonos Oncology Corporation
Duke University
Arvinas Inc.
Immatics US, Inc.
BioInvent International AB
Aulos Bioscience, Inc.
M.D. Anderson Cancer Center
Essen Biotech
Essen Biotech
Sapience Therapeutics
Sanofi
University of California, Davis
Teva Branded Pharmaceutical Products R&D, Inc.
Beijing Tide Pharmaceutical Co., Ltd
IDEAYA Biosciences
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Second Life Therapeutics
Onchilles Pharma Inc
NuCana plc
Ohio State University Comprehensive Cancer Center
Shanghai JMT-Bio Inc.
Brown University
Swiss Cancer Institute
M.D. Anderson Cancer Center
Shanghai Juncell Therapeutics
Linnaeus Therapeutics, Inc.
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
University of Colorado, Denver